Physician profile
Robert J Schmidt
NPI 1780688481
$17,416.70
in general payments reported to CMS, 2019-2025
26 companies · $3,728 in 2025
The $3,728 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,673 · 2020: $346 · 2021: $63.26 · 2022: $190 · 2023: $8,007 · 2024: $2,410 · 2025: $3,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,756 · Travel and Lodging: $157 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,200.00 |
| Food and Beverage | $1,755.85 |
| Travel and Lodging | $157.20 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,559.10 | 2019-2025 | Repatha, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $473.66 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $450.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $425.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $289.41 | 2019-2020 | |
| Pfizer INC. | $178.90 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $158.95 | 2019-2024 | Eliquis |
| Abbvie INC. | $139.70 | 2021-2025 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $129.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $111.51 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $101.94 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $60.26 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.56 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $43.72 | 2019 | |
| Lilly USA, LLC | $43.32 | 2019-2024 | Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.69 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $28.36 | 2019 | |
| Shield Therapeutics INC | $18.82 | 2024 | |
| Amryt Pharma Holdings Ltd | $17.80 | 2022 | |
| Astellas Pharma US INC | $17.42 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.84 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.33 | 2022 | |
| Amarin Pharma, INC. | $16.31 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.65 | 2019 | |
| Sanofi Pasteur INC. | $10.90 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.